Cabinet of Ministers of the Russian Federation allowed Pharmasintez JSC to produce the drug Remdesivir for coronavirus until the end of 2021 without consent of patent holders. The drug will be released under the brand name Remdeform. Gilead Sciences owns the patent rights to the drug and will receive compensation ranging from β‚½1 million to β‚½5 million one time.